Sign in
Stories
Biotech Startups and Gene Therapy for Hearing Loss
Share
Afya Limited Expands Medical Seats in Br...
BioSenic's Progress and Patent
Biopharma Companies Announce Public Offe...
Overview
API
Sensorion, a biotechnology company, is participating in the ARO Midwinter Meeting to present its gene therapy programs for hearing loss disorders. The company's focus is on developing treatments for hereditary forms of deafness, including SENS-501 for otoferlin-related deafness and GJB2-GT for GJB2-related deafness. Additionally, the article provides a directory of startups in the biotech sector in Japan, highlighting 395 unlisted startups with outstanding technologies and business models. Abacus Group's Meena Jeenarain has been recognized for promoting female representation in technology and data disciplines. The 'Directory of Biotech Startups in Japan 2021-2022' features 395 selected startups with promising futures in the biotech sector.
Ask a question
How might the advancements in gene therapy for hearing loss disorders impact the biotech industry and patient treatment options?
What are the potential implications of the 'Directory of Biotech Startups in Japan 2021-2022' for global collaborations and advancements in the biotech field?
What strategies can be employed to promote diversity and inclusion in the biotech sector, as seen in Abacus Group's recognition of Meena Jeenarain?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Oct 2023
Nov 2023
Dec 2023
Jan 2024
Coverage
abacu
bioja
klog.
resea